Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2007-01-23
2007-01-23
Kwon, Brian (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S291000, C514S311000, C514S312000, C514S314000
Reexamination Certificate
active
10740182
ABSTRACT:
The invention provides methods and compositions for reducing platelet activation, platelet aggregation and thrombosis. The invention further provides compositions and methods for treating or preventing diseases or disorders in which the pathology of the disease or disorder involves one or more of platelet activation, platelet aggregation and thrombus formation. The invention additionally relates to the use of protein palmitoylation inhibitors for the reduction of platelet activation, platelet aggregation and thrombosis, as well as to the use of protein palmitoylation as a target for the identification of inhibitors of platelet activation, platelet aggregation and thrombosis.
REFERENCES:
patent: 3755332 (1973-08-01), Wasley et al.
patent: 4011832 (1977-03-01), Westervelt et al.
patent: 4361563 (1982-11-01), Austel et al.
patent: 4616018 (1986-10-01), Hauel et al.
patent: 4699909 (1987-10-01), Hauel et al.
patent: 4923869 (1990-05-01), Prucher et al.
patent: 4954499 (1990-09-01), Prucher
patent: 4954501 (1990-09-01), Herter et al.
patent: 4957920 (1990-09-01), Morsdorf et al.
patent: 4968683 (1990-11-01), Morsdorf et al.
patent: 5039675 (1991-08-01), Morsdorf et al.
patent: 6801405 (2004-10-01), Boutaghou et al.
patent: 6818772 (2004-11-01), Kym et al.
“WIN 17317-3, a New High-Affinity Probe for Voltage-Gated Sodium Channels”, Wanner et al., Biochemistry, 1999, vol. 38, No. 34, pp. 11137-11146.
Xu et al., Hecheng Huaxue, 1999, abstract, 7(2), pp. 194-197.
Eggert et al., Archiv der Pharmazie, abstract, 1990, 323(9), pp. 611-618.
Omburo, et al., “Divalent Metal Cation Requirement and Possible Classification of cGMP-Inhibited Phosphodiesterase as a Metallohydrolase”, Archives of Biochemistry and Biophysics (1995), V. 323, pp. 1-5.
Chou, et al., “Mechanism of Inhibition of Platelet Aggregation by HCL-31D”, European Journal of Pharmacology (2000), V. 387, pp. 125-131.
Coughlin, “Thrombin Signalling and Protease-Activated Receptors”, Nature (2000), V. 407, pp. 258-264.
Offermans, et al., “Defective Platelet Activation in Gαq-Deficient Mice”, Nature (1997), V. 389, pp. 183-186.
Palabrica, et al., “Leukocye Accumulation Promoting Fibrin Deposition is Mediatedin vivoby P-Selectin on Adherent Platelets”, Nature (1992), V. 359, pp. 848-851.
Bazzoni, et al., “Platelet-Neutrophil Interactions. Possible Relevance in the Pathogenesis of Thrombosis and Inflammation”, Haematologica (1991), V. 76, pp. 491-499.
Kazura, “Platelet-Neutrophil Interaction: Modulation of the Inflammatory Response”, Journal of Laboratory and Clinical Medicine (1989), V. 114, pp. 469-470.
Liu & Sylvester, “The Inhibitory Effect of 9-Amino-1,2,3,4-Tetrahydroacridine (THA) on Platelet Function”, Thrombosis Research (1992), V. 67, pp. 533-544.
Kanaho, et al., “Mechanism of Inhibitory Effect of Some Amphiphilic Drugs on Platelet Aggregation Induced by Collagen, Thrombin or Arachidonic Acid”, Thrombosis Research (1983), V. 31, pp. 817-831.
Beebe, et al., “A New Pharmacological Treatment for Intermittent Claudication: Results of a Randomized, Multicenter Trial”, Archives of Internal Medicine (1999), V. 159, pp. 2041-2050.
DeVos, et al., “Cellular Pharmacology of Cerulenin Analogs that Inhibit Protein Palmitoylation”, Biochemical Pharmacology (2001), V. 62, pp. 985-995.
Hirose, et al., “Antithrombotic Activity of NSP-513, a Novel Selective Phosphodiesterase 3 Inhibitor, on Femoral Arterial Thrombosis Induced by Physical Stenosis and Electrical Current: Comparison of Antithrombotic and Hemodynamic Effects”, Journal of Cardiovascular Pharmacology (2000), V. 35, pp. 586-594.
Jacob, et al., “Endothelial Cell Apoptosis is Accelerated by Inorganic Iron and Heat Via an Oxygen Radical Dependent Mechanism”, Surgery (1997), V. 122, pp. 243-254.
Papayianni, et al., “Transcellular Biosynthesis of Lipoxin A4During Adhesion of Platelets and Neutrophils in Experimental Immune Complex Glomerulonephritis”, Kidney International (1995), V. 47, pp. 1295-1302.
Chen, et al., “Effects of CI-930, a Novel Phosphodiesterase III Inhibitor, on Platelt Aggregation and Arahidonic Acid Metabolism”, Acta Pharmacologica Sinica (1990), V. 11, pp. 338-343.
Yamakodo, et al., “Mepacrine-Induced Inhibition of Human Platelet Cyclic-GMP Phosphodiesterase”, BBA-Biochimica Biophysica Acta (1984), V. 801, pp. 111-116.
Sloan, et al., “Protein Kinase C-Dependent and Ca2+-Dependent Mechanisms of Secretion from Streptolysin O-Permeabilized Platelets: Effects of Leakage of Cytosolic Proteins”, Biochemical Journal (1997), V. 328, pp. 13-21.
van Willigen & Akkerman, Protein Kinase C and Cyclic AMP Regulate Reversible Exposure of Binding Sites for Fibrinogen on the Glycoprotein IIB-IIIA Complex of Human Platelets, Biochemical Journal (1991), V. 273, pp. 115-120.
White & Raynor, “The Effect of Phenothiazine and Non-Phenothiazine Inhibitors of Calmodulin on Platelet Calcium Fluxes”, Biochemical and Biophysical Research Communications (1982), V. 104, pp. 1066-1072.
Chung, et al., “Protein Kinase C Phosphorylation of Syntaxin 4 in Thrombin-Activated Human Platelets”, Journal of Biological Chemistry (2000), V. 275, No. 33, pp. 25286-25291.
Fratti, et al., Endothelial Cell Injury Caused byCandida AlbicansIs Dependent on Iron, Infection and Immunity (1998), V. 66, pp. 191-196.
Hirose, et al., “Antiplatelet and Antithrombotic Effects of a Novel Selective Phosphodiesterase 3 Inhibitor, NSP-513, in Mice and Rats”, Japanese Journal of Pharmacology (2000), V. 82, pp. 188-198.
Rosen, et al., “Laser-Induced Noninvasive Vascular Injury Models in Mice Generate Platelet- and Coagulation-Dependent Thrombi”, American Journal of Pathology (2001), V. 158, No. 5, pp. 1613-1622.
Brufani, et al., “Synthesis of Phenothiazine Derivatives as Potential Inhibitors of Phospholipase C.”, Farmaco (1992), V. 47, pp. 585-597.
Rinder & Fitch, “Amplification of the Inflammatory Response: Adhesion Molecules Associated with Platelet/White Cell Responses”, Journal of Cardiovascular Pharmacology (1996), V. 27, Suppl. 1, pp. 6-12.
Beth Israel Deaconess Medical Center
Edwards Angell Palmer & & Dodge LLP
FitzGerald Mark J.
Kwon Brian
Williams Kathleen M.
LandOfFree
Methods for reducing platelet activation platelet aggregaton... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods for reducing platelet activation platelet aggregaton..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for reducing platelet activation platelet aggregaton... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3814554